8-K - Sangamo Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Securities Issuance

Exhibits On

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. Underwritten Offering On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an u

Material Agreement

$25.0M

3.02

Unregistered Sales of Equity Securities. The information set forth in Item 1.01 of this Current Report on Form 8-K relating to the Warrant Amendment is incorpor

Securities Issuance

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 1.1 Underwriting Agreement, dated February 3, 2026, by and between Sangamo Therapeuti

Exhibits Only

Exhibits (5)

1.1

EX-1.1

4.1

EX-4.1

4.2

EX-4.2

5.1

EX-5.1

8-K